AbbVie purchases Capstan Therapeutics for $2.1bn to strengthen immunology portfolio

From Yahoo Finance: 2025-07-01 07:38:00

AbbVie has acquired Capstan Therapeutics for up to $2.1bn, gaining a high-risk, high-reward in vivo CAR-T candidate. Capstan’s therapy, CPTX2309, aims to address current CAR-T limitations, offering a promising solution with strong B-cell depletion results in a Phase I study. AbbVie’s acquisition reflects a strategic effort to strengthen its immunology franchise.

Investors responded positively to the news, with AbbVie’s shares closing 1.7% higher at $185.62 upon announcement. This move follows AbbVie’s previous collaboration with Umoja Biopharma on in-situ generated CAR-T therapies. Analysts see potential in Capstan’s technology, acknowledging the clinical risks but highlighting the long-term benefits of in vivo CAR-T therapies.

Capstan’s CEO views in vivo CAR-T as a transformative treatment modality with broad potential in medicine. Other biotechs in this space, like Interius BioTherapeutics, use different vectors for in vivo CAR-T generation. AbbVie’s purchase of Capstan’s technology aligns with the FDA’s recent removal of access barriers for CAR-T therapies, signaling a positive outlook for the sector.

AbbVie’s acquisition of Capstan Therapeutics for $2.1bn underscores the company’s commitment to innovation in immunology. With Capstan’s in vivo CAR-T technology, AbbVie aims to address current therapy limitations and pave the way for transformative treatments in autoimmune diseases. This strategic move aligns with AbbVie’s strong market performance and long-term growth prospects.



Read more at Yahoo Finance: AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline